HR Execs on the Move

Cynosure

www.cynosure.com

 
Cynosure develops and markets laser and light-based aesthetic treatment systems that enable plastic surgeons, dermatologists and other medical practitioners to perform non-invasive and minimally invasive procedures to remove hair, treat vascular and benign pigmented lesions, remove multi-colored tattoos, revitalize the skin, liquefy and remove unwanted fat through laser lipolysis, reduce cellulite, clear nails infected by toe fungus and ablate sweat glands. Cynosure`s product portfolio is composed of a broad range of energy sources including Alexandrite, diode, Nd: YAG, picosecond, pulse dye, and Q-switched lasers and intense pulsed light. Cynosure sells its products globally under the Cynosure, Palomar and ...
  • Number of Employees: 250-1000
  • Annual Revenue: $250-500 Million

Executives

Name Title Contact Details
DenaRae Walter
 Interim Head of Human Profile
Tim Harrah
 VP, R&D Profile
Sujat Sukthankar
 Executive Vice President, Research & Product Development Profile
James Boll
 SVP New Product Development Profile
Sean Trainor
 Chief Supply Chain Officer Profile

Similar Companies

Optovue Inc

Optovue Inc is a Fremont, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

McDalt Medical Corp

McDalt Medical Corp is a Arlington, TX-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Meridian Medical Inc

Meridian Medical Inc is a Newport Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

CooperSurgical

CooperSurgical is the leading company dedicated to providing medical devices and procedure solutions that improve health care delivery to women regardless of clinical setting. Our company is fostering that position through expansion of its core

NeuroOne Incorporated

NeuroOne Medical Technologies Incorporated (Ticker: NMTC) is a medical technology company focused on improving surgical care options and outcomes for patients suffering from neurological disorders, initially targeting epilepsy. Today, our attention is on the development and commercialization of patented thin-film, cortical electrode technology for intracranial electroencephalography (iEEG) and depth electrodes for stereoelectroencephalography (sEEG) recording of brain activity. The products currently available in these categories have significant limitations such as low recording resolution and high risk of infection. NeuroOne believes our technology can address these unmet needs upon initial commercialization with pipeline technology to advance the field by enabling minimally invasive techniques and all-in-one diagnostic and therapeutic options. While our initial focus is Epilepsy, future applications in Parkinson`s disease, Essential tremors, and Dystonia are within sight. NeuroOne technologies will be presented to a well-defined market, eager for the advancement they bring. There are 188 hospital centers licensed to perform epilepsy surgical procedures in the U.S. The current addressable market opportunity for is approximately $525.6 million. As more patients choose the minimally invasive procedures made available by NeuroOne technology, the future opportunity is estimated to be approximately $14.9 billion with full market penetration.